Chitosan-associated SLN: in vitro and ex vivo characterization of cyclosporine A loaded ophthalmic systems

References

• Başaran E, Demirel M, Sırmagül B, Yazan Y. Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery. J Microencapsul 2010; 27: 37–47
   PubMed Web of Science ®Google Scholar
• Bravo Gonzalez RC, Huwyler J, Walter I, Mountfield R, Bitter B. Improved oral bioavailability of cyclosporine A in male Wistar rats. Comparison of a Solutol HS 15 containing self-dispersing formulation and a microsuspension. Int J Pharm 2002; 245: 143–51
   PubMedGoogle Scholar
• Burgalassi S, Chetoni P, Monti D, Saettone F. Cytotoxicity of potential ocular permeation enhancers evaluated on rabbit and human corneal epithelial cell lines. Toxicol Lett 2001; 122: 1–8
   PubMed Web of Science ®Google Scholar
• Burgalassi S, Monti D, Brignoccoli A, Fabiani O, Lenzi C, Pirone A, Chetoni P. Development of cultured rabbit corneal epithelium for drug permeation studies: A comparison with excised rabbit cornea. J Ocul Pharmacol Ther 2004; 20: 518–32
   PubMed Web of Science ®Google Scholar
• Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Novel hydrophilic chitosan–polyethylene oxide nanoparticles as protein carriers. J Appl Polym Sci 1997; 63: 125–32
   Web of Science ®Google Scholar
• Cavalli R, Gasco MR, Chetoni P, Burgalassi S, Saettone MF. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm 2002; 238: 241–5
   PubMed Web of Science ®Google Scholar
• De Campos A, Sanchez A, Gref R, Calvo P, Alonso MJ. The effect of a PEG versus a chitosan on the interaction of drug colloidal carriers with the ocular mucosa. Eur J Pharm Sci 2003; 20: 73–81
   PubMed Web of Science ®Google Scholar
• Dick Andrew D, Azim M, Forrester J. Immunosuppressive therapy for chronic uveitis: Optimising therapy with steroids and cyclosporin A. Br J Ophthalmol 1997; 81: 1107–12
   PubMedGoogle Scholar
• Fotakis G, Timbrell JA. In vitro cytoxicity assays: Comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride. Toxicol Lett 2006; 160: 171–7
   PubMed Web of Science ®Google Scholar
• Garcia-Fuentes M, Prego C, Torres D, Alonso MJ. A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery. Eur J Pharm Sci 2005; 25: 133–43
   PubMed Web of Science ®Google Scholar
• Gokce EH, Sandri G, Bonferoni MC, Rossi S, Ferrari F, Gueneri T, Caramella C. Cyclosporine A loaded SLN: Evaluation of cellular uptake and corneal cytotoxicity. Int J Pharm 2008; 364: 76–86
   PubMed Web of Science ®Google Scholar
• Husek A. High performance liquid chromatography cyclosporine A and its oral solution. J Chromatogr A 1997; 759: 217–24
   PubMed Web of Science ®Google Scholar
• Illum L. Chitosan and its use as a pharmaceutical excipient. Pharm Res 1998; 15: 1326–31
   PubMed Web of Science ®Google Scholar
• Kuwano M, Ibuki H, Morikawa N, Ota A, Kawashima Y. Cyclosporine A formulation affects its ocular distribution in rabbits. Pharm Res 2002; 19: 108–11
   PubMed Web of Science ®Google Scholar
• Mehnert W, Mader K. Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev 2001; 47: 165–96
   PubMed Web of Science ®Google Scholar
• Midelfart A, Dybdahl A, Krane J. Detection of dexamethasone in the cornea and lens by NMR spectroscopy. Graefes Arch Clin Exp Ophthalmol 1999; 237: 415–23
   PubMed Web of Science ®Google Scholar
• Mochizuki M, DeSmet M. Use of immunosuppressive agents in ocular diseases. Progr Retin Eye Res 1994; 13: 479–506
   Google Scholar
• Muller RH, Runge S, Ravelli V, Mehnert W, Thunemann AF, Souto EB. Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN®) versus drug nanocrystals. Int J Pharm 2006; 317: 82–9
   PubMed Web of Science ®Google Scholar
• Niu M, Shi K, Sun Y, Wang J, Cui F. Preparation of CyA-loaded solid lipid nanoparticles and application on ocular preparations. J Drug Deliv Sci Technol 2008; 18: 293–7
   Web of Science ®Google Scholar
• Peetla C, Labhasetwar V. Effect of molecular structure of cationic surfactants on biophysical interactions of surfactant-modified nanoparticles with a model membrane and cellular uptake. Langmuir 2009; 25: 2369–77
   PubMed Web of Science ®Google Scholar
• Popiolkiewicz J, Polkowski K, Skierski JS, Mazurek AP. In vitro toxicity evaluation in the development of new anticancer drugs—Genistein glycosides. Cancer Lett 2005; 229: 67–75
   PubMed Web of Science ®Google Scholar
• Qaqish RB, Amiji MM. Synthesis of a fluorescent chitosan derivative and its application for the study of chitosan–mucin interactions. Carbohydr Polym 1999; 38: 99–107
   Web of Science ®Google Scholar
• Reichl S. Cell culture models of the human cornea – A comparative evaluation of their usefulness to determine ocular drug absorption in-vitro. J Pharm Pharmacol 2008; 60: 299–307
   PubMed Web of Science ®Google Scholar
• Riddick TM, 2007. Control of colloid stability, Zeta potential. Zeta-Meter Inc., 765 Middlebrook Ave, Staunton, VA 24401, 2007, 198–200
   Google Scholar
• Rossi S, Marciello M, Sandri G, Bonferoni MC, Ferrari F, Caramella C. Chitosan ascorbate: A chitosan salt with improved penetration enhancement properties. Pharm Dev Tech 2008; 13: 513–21
   PubMed Web of Science ®Google Scholar
• Sandri G, Bonferoni MC, Rossi S, Ferrari F, Gibin S, Zambito Y, Di Colo G, Caramella C. Nanoparticles based on N-trimethylchitosan: Evaluation of absorption properties using in vitro (Caco-2 cells) and ex vivo (excised rat jejunum) models. Eur J Pharm Biopharm 2007; 65: 68–77
   PubMed Web of Science ®Google Scholar
• Schwarz C, Mehnert W. Freeze-drying of drug-free and drug-loaded solid lipid nanoparticles (SLN). Int J Pharm 1997; 157: 171–9
   PubMed Web of Science ®Google Scholar
• Ugazio E, Cavalli R, Gasco MR. Incorporation of cyclosporine A in solid lipid nanoparticles (SLN). Int J Pharm 2002; 241: 341–4
   PubMed Web of Science ®Google Scholar